Jennifer L. Taylor-Cousar, MD, MSCS Make an Appointment Ask a Question Refer Patient Jennifer L. Taylor-Cousar, MD, is a pediatric and adult pulmonologist at National Jewish Health. Dr. Taylor-Cousar sees pediatric and adult pulmonary patients. Medical Director, Clinical Research Services Co-Director, Adult Cystic Fibrosis Program Director, Cystic Fibrosis Therapeutics Development Center Adult Program Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine Division of Pediatric Pulmonary Medicine Department of Pediatrics 5280 Top Doctors 2019 Previously a 5280 Top Doctor America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd. Recognized in America’s Top Doctors — Castle Connolly, Inc. Best Doctors in America® 2018-2019 — Best Doctors, Inc. Recognized in Best Doctors in America® — Best Doctors, Inc. America’s Top Doctors 2019 — Castle Connolly Medical, Ltd. Email Profile Print Profile × No Rating Available In order to provide the most accurate and useful information on our providers, we only post satisfaction data when a provider has received a minimum of 30 survey responses. We have not yet received the minimum number of surveys for this provider, or this provider is a researcher who only sees a limited number of patients in clinic. To learn more about this survey, visit our about the Press Ganey Survey page. Overview Contact Info & Locations Programs & Services Cystic Fibrosis Program (Adult) Department of Medicine Division of Pediatric Pulmonary Medicine Division of Pulmonary, Critical Care and Sleep Medicine (Adult) National Jewish Health for Kids / Pediatric Programs Pulmonary Diagnostic Center (Pediatric) Specialties & Conditions Cystic Fibrosis (CF) Pediatric Lung Disease Research Areas Cystic Fibrosis (CF) Related Clinical Trials Cystic Fibrosis Medication for Gating Mutations Impact of triple Combination Therapy for People with CF with Sinusitis Sexual and Reproductive Health Survey of Women with Cystic Fibrosis The PROMISE Study: An Observational Study of Triple Combination Therapy for Cystic Fibrosis Triple Combination CF Medication for Less Common Genetic Mutations Special Interests Research Interests Cystic Fibrosis, innate immunity, CFTR function, clinical research See More View Curriculum Vitale View Publications News & Videos Triple-Combination Therapy Helps More People with Cystic Fibrosis Triple-Combination Therapy Helps Patients with Cystic Fibrosis Education Education 1998 Duke University Medical Center (Durham, NC), MD 1993 Stanford University (Stanford, CA), BA, Human Biology Residency 1998 - 2002 Duke University Medical Center, Internal Medicine and Pediatrics Fellowship 2002 - 2006 Duke University Medical Center, Adult and Pediatric Pulmonary Medicine Awards & Recognition 2016: Physician of the Year, Colorado Society for Respiratory Care, Denver, CO 2015: Science Transforming Life Award, National Jewish Health, Denver, CO 2014: Viola Vestal Coulter Research Fellow Award 2009: Cystic Fibrosis Research Institute Professional of the Year Award 2009: Selected participant, AAMC Early Career in Medicine Early Career Women Faculty Professional Development Seminar 2008: Clinical Trials Center New Investigator of the Year Award 2006: Duke University Pulmonary Fellowship Scientific Achievement Award 2005: 2nd Place, Fellows’ Clinical Research Presentations, Respiratory Disease Young Investigators Forum 2003: Cystic Fibrosis Foundation Clinical Fellowship Board Certification 11/2008: ABP, Subspecialty in Pediatric Pulmonary 10/2006: ABIM, Subspecialty in Pulmonary Disease 8/2004: American Board of Internal Medicine 8/2002: American Board of Pediatrics Professional Memberships Member, American Thoracic Society European Cystic Fibrosis Society Publications Heijerman HGM, * McKone EF*, Downey DG, Braeckel E,Rowe SM, Tullis E. Mall M, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL*, and McCoy K* on behalf of the VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for theF508delmutation: a double-blind, randomised, phase 3 trial.*equal contributions Lancet. 2019 Oct 30. pii: S0140-6736(19)32597-8. doi: 10.1016/S0140-6736(19)32597-8. PMID: 31679946 Middleton PG*, Mall MA*, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW,Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM** and Jain R** for the VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation.New Eng J Med. 2019. Epub ahead of print Downey DG andTaylor-Cousar JL. Challenges and opportunities in the development of future CFTR modulator options for people with CFPMID: 31672556 Keating D, Sass L Burr L, Daines C, Rowe S, Savage J, Simard C, Xuan F, Van Goor F, Robertson S, McKee C, Waltz D, Marigowda G, and Taylor-Cousar JL (corresponding author). VX-445 in Combination with Tezacaftor-Ivacaftor in Phe508del Homozygous and Heterozygous Patients with Cystic Fibrosis. N Engl J Med 2018; 379:1612-1620 DOI: 10.1056/NEJMoa1807120 PMID: 30334692 Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone E, Plant B, Paris D, Ramsey B, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. Triple Combination of VX-659/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and One or Two F508del-CFTR Alleles. N Engl J Med 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119 PMID: 303334693 Hospital Affiliations Children's Hospital ColoradoSt. Joseph Hospital - DenverUniversity of Colorado Hospital Academic Affiliations 2009-Present: Assistant Professor, Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine and the Department of Pediatrics, Pulmonary Division, University of Colorado Denver. Teaching & Professional Positions 2012: Board Member, Colorado CFF Chapter 5/2009-Present: American Thoracic Society 2010: Clinical Problems Program Committee Conflicts of Interest National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations. Ask a Question through Patient Portal Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account Contact Information Office: 877.225.5654 Locations National Jewish Health Main Campus 1400 Jackson St. Denver, CO 80206 Saint Joseph Hospital 1835 Franklin Street Denver, CO 80218 Patient Ratings The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes. Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey. Comments Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.